Expression and Clinical Significance of Th1/Th2/Th17 Cytokines and Lymphocyte Subsets in PCNSL

References

• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17(Suppl4):iv1–iv62.
   PubMed Web of Science ®Google Scholar
• Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797–1807.
   PubMed Web of Science ®Google Scholar
• King RL, Goodlad JR, Calaminici M, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Archiv. 2020;476(5):647–665.
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Lymphoma and Leukemia of the Nervous System. Eur J Neurol. 2012;19(5):e53–e53.
   Google Scholar
• Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–1418.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhang W, Zhang L, et al. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma. Sci Rep. 2016;6:38671.
   PubMed Web of Science ®Google Scholar
• Shao J, Chen K, Li Q, et al. High Level of IL-10 in Cerebrospinal Fluid is Specific for Diagnosis of Primary Central Nervous System Lymphoma. Cancer Manag Res. 2020;12:6261–6268.
   PubMed Web of Science ®Google Scholar
• Yadahalli R, Sarode GS, Sarode SC, et al. CC group of chemokines and associated gene expression of transcription factors: deciphering immuno-pathogenetic aspect of oral submucous fibrosis. Disease Month. 2022;1:101351.
   Google Scholar
• Béné MC, Lacombe F, Porwit A. Unsupervised flow cytometry analysis in hematological malignancies: a new paradigm. Int J Lab Hematol. 2021;43(Suppl 1):54–64.
   PubMed Web of Science ®Google Scholar
• Barajas RF, Politi LS, Anzalone N, et al. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology. 2021;23(7):1056–1071.
   PubMed Web of Science ®Google Scholar
• Kalia V, Sarkar S. Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act. Front Immunol. 2018;9:2987.
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240(4856):1169–1176.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou N, Zhou L, et al. IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol. 2021;22(3):358–369.
   PubMed Web of Science ®Google Scholar
• Beltra JC, Bourbonnais S, Bédard N, et al. IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. Proc Natl Acad Sci U S A. 2016;113(37):E5444–5453.
   PubMed Web of Science ®Google Scholar
• Shevach EM. Application of IL-2 therapy to target T regulatory cell function. Trends Immunol. 2012;33(12):626–632.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–190.
   PubMed Web of Science ®Google Scholar
• Fishman M, Dutcher JP, Clark JI, et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry. J Immunother Cancer. 2019;7(1):84.
   PubMed Web of Science ®Google Scholar
• Davar D, Ding F, Saul M, et al. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017;5(1):74.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Dutcher JP, Daniels GA, et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019;7(1):49.
   PubMed Web of Science ®Google Scholar
• Glasner A, Levi A, Enk J, et al. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018;48(2):396–398.
   PubMed Web of Science ®Google Scholar
• Markovic O, Popovic L, Marisavljevic D, et al. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med. 2014;25(3):296–302.
   PubMed Web of Science ®Google Scholar
• Knörr F, Damm-Welk C, Ruf S, et al. Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica. 2018;103(3):477–485.
   PubMed Web of Science ®Google Scholar
• Capobianchi MR, Uleri E, Caglioti C, Dolei A. Type I IFN family members: similarity, differences and interaction. Cytokine Growth Factor Rev. 2015;26(2):103–111.
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Bagni R, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res. 2011;71(14):4898–4907.
   PubMed Web of Science ®Google Scholar
• Ngoenkam J, Schamel WW, Pongcharoen S. Selected signalling proteins recruited to the T-cell receptor-CD3 complex. Immunology. 2018;153(1):42–50.
   PubMed Web of Science ®Google Scholar
• Batorov EV, Pronkina NV, Tikhonova MA, et al. Increased circulating CD3(+) T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2019;60(10):2488–2497.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–854.
   PubMed Web of Science ®Google Scholar
• Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J clin oncol. 2003;21(12):2342–2348.
   PubMed Web of Science ®Google Scholar
• Kusano Y, Yokoyama M, Terui Y, et al. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma. Blood Cancer J. 2017;7(4):e558.
   PubMed Web of Science ®Google Scholar
• Saligrama N, Zhao F, Sikora MJ, et al. Opposing T cell responses in experimental autoimmune encephalomyelitis. Nature. 2019;572(7770):481–487.
   PubMed Web of Science ®Google Scholar
• Peng M, Xiao-Long LU, Zhang L, Hong XU, Laboratory DO. Significance of T lymphocyte subsets and NK cells in the treatment of diffuse large B-cell lymphoma patients. Practical J Clin Med. 2018;1:548.
   Google Scholar
• Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356–371.
   PubMed Web of Science ®Google Scholar
• Shirley M. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: their Use and Differential Features. Target Oncol. 2022;17(1):69–84.
   PubMed Web of Science ®Google Scholar
• Yu H, Wang X, Li J, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Therapy Oncol. 2021;21:158–170.
   PubMed Web of Science ®Google Scholar
• Guo Y, Liu Y, Hu N, et al. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. J Med Chem. 2019;62(17):7923–7940.
   PubMed Web of Science ®Google Scholar
• Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851–859.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Wang WH, Dong M, et al. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. Invest New Drugs. 2022;40(3):650–659.
   PubMed Web of Science ®Google Scholar